Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study
Long-term MARS study data are consistent with the known safety profile of mepolizumab. Over 192 weeks (pre-mepolizumab observation), mepolizumab was well tolerated, with improvements in eosinophilic granulomatosis with polyangiitis disease control and reductions in oral glucocorticoid use.
Authors
- Hideaki Kunishige
- Masaki Komatsubara
- Tomonori Ishii (ORCID: https://orcid.org/0000-0001-5361-5824)
- Peter Howarth (ORCID: https://orcid.org/0000-0003-0619-7927)
- Etsuko Hayashi
- J Tamaoki
- Rafael Alfonso-Cristancho
- T Kobayashi
Institutions
- Tohoku University Hospital (JP)
- GlaxoSmithKline (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Tokyo Women's Medical University (JP)
- Tohoku Medical and Pharmaceutical University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1093/mr/roae100
- Citations
- 6
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 2.82